What's Hot

View all perspectives
      RT @AurelieRheumo: Sarilumab in PMR

      SAPHYR Phase 3 RCT
      Underpowered (<50% target recruitment)

      -% remission sustaine

      Aurelie Najm AurelieRheumo

      2 years 5 months ago
      Sarilumab in PMR SAPHYR Phase 3 RCT Underpowered (<50% target recruitment) -% remission sustained from wk12 to wk 52 28% vs 10% PBO -Risk of flare reduced HR 0.56 -Improvement of several PROs No new safety signal LB0006 @RheumNow #EULAR2022 https://t.co/n7WdQxQaHo
      RT @KDAO2011: SAPHYR phase 3 RDBPCT study: #sarilumab vs PCB for relapsing #PMR on pred 7.5+ mg/d. Study met endpoints

      TheDaoIndex KDAO2011

      2 years 5 months ago
      SAPHYR phase 3 RDBPCT study: #sarilumab vs PCB for relapsing #PMR on pred 7.5+ mg/d. Study met endpoints (whether of or not CRP was included). Time to first flare was longer w/SARI, less steroid use, and also better PROs. AE: #EULAR2022 LB0006 @rheumnow 1/2 https://t.co/lIspLKlveb
      RT @Yuz6Yusof: #LB0002 #EULAR2022 An interesting study design looking at flare rate following withdrawal of drug after W

      Md Yuzaiful Md Yusof Yuz6Yusof

      2 years 5 months ago
      #LB0002 #EULAR2022 An interesting study design looking at flare rate following withdrawal of drug after WK12. Phase 3 RCT of Baricitinib in paediatric JIA showed 76% met ACR30 at WK12. The Double-blind withdrawal showed less patients on Bari flared vs PBO (17% vs 51%) @RheumNow https://t.co/T0mSDkoHJo
      RT @RichardPAConway: Ramanan et al Baricitinib in JIA. Double blind withdrawal study of prior responders. Earlier flare

      Richard Conway RichardPAConway

      2 years 5 months ago
      Ramanan et al Baricitinib in JIA. Double blind withdrawal study of prior responders. Earlier flare with PBO vs bari (HR 0.24 [95%CI 0.13,0.45], p<0.001. Less flares with bari vs PBO (17.1% vs 50.6%) p<0.001 @RheumNow #EULAR2022 LB0002 https://t.co/22rp70njRu https://t.co/LtJE9dz0GT
      RT @RichardPAConway: Kohm et al. Efficacy of IL12/23i ustekinumab independent of MTX in PsA. No additive benefit of MTX

      Richard Conway RichardPAConway

      2 years 5 months ago
      Kohm et al. Efficacy of IL12/23i ustekinumab independent of MTX in PsA. No additive benefit of MTX on joint, skin, QoL, function @RheumNow #EULAR2022 POS1059
      RT @KDAO2011: Phase 3 compared Bimekizumab to PCB and Humira; it met all endpoints for PsA; the drug inhibits both IL17F

      TheDaoIndex KDAO2011

      2 years 5 months ago
      Phase 3 compared Bimekizumab to PCB and Humira; it met all endpoints for PsA; the drug inhibits both IL17F & IL-17A. Safety signal: increase fungal (candidal) infx #EULAR2022 LB0001 @rheumnow https://t.co/MJJwj44YgU
      RT @RichardPAConway: McInnes @IainBMcInnes1 et al. Bimekizumab (IL17A/Fi) in PsA. BE OPTIMAL 852 patient RCT vs PBO vs A

      Richard Conway RichardPAConway

      2 years 5 months ago
      McInnes @IainBMcInnes1 et al. Bimekizumab (IL17A/Fi) in PsA. BE OPTIMAL 852 patient RCT vs PBO vs ADA. Looks same for joints, better for skin than ADA (not stat sig) @RheumNow #EULAR2022 LB0001 https://t.co/oKEHJE3tGn https://t.co/H7nPnbEWUB
      RT @synovialjoints: Novel ePROMS use. Use of ePROMS RAPID3/PASS and asking patients if they had a flare had high diagnos

      Dr. Antoni Chan synovialjoints

      2 years 5 months ago
      Novel ePROMS use. Use of ePROMS RAPID3/PASS and asking patients if they had a flare had high diagnostic accuracy identifying those not needing DMARD or steroid intensification up and eligible to skip their next outpatient clinic visit. Seppen et al #EULAR2022 @RheumNow POS0381
      RT @synovialjoints: Bimekizumab (BKZ) vs PBO at 16 week BE COMPLETE for PsA with inadequate response to TNFi ACR50 44% v

      Dr. Antoni Chan synovialjoints

      2 years 5 months ago
      Bimekizumab (BKZ) vs PBO at 16 week BE COMPLETE for PsA with inadequate response to TNFi ACR50 44% vs 7%,PASI90 69% vs 7%, ACR20 67% vs 16%, ACR70 27% vs 0.8%, PASI 100 60% vs 5%, MDA 44% vs 6%, no new safety signals #EULAR2022 @RheumNow OP0255 Merola et al https://t.co/riU2sIXGs9
      RT @ericdeinmd: #EULAR2022 LB002
      P3 Double-Blind W/d study: Baricitinib for JIA
      ⭐️All pts start in open label w good

      Eric Dein ericdeinmd

      2 years 5 months ago
      #EULAR2022 LB002 P3 Double-Blind W/d study: Baricitinib for JIA ⭐️All pts start in open label w good benefit (1/2 with ACR70) ⭐️PBO W/d led to 50% flare vs 17% in BARI group, flares earlier @RheumNow https://t.co/apSSLqu1mp
      RT @Yuz6Yusof: #LB0005 #EULAR2022 Phase 3 RCT of Bimekizumab, dual IL17A and 17F inhibitor in bDMARDs-naive PsA showed s

      Md Yuzaiful Md Yusof Yuz6Yusof

      2 years 5 months ago
      #LB0005 #EULAR2022 Phase 3 RCT of Bimekizumab, dual IL17A and 17F inhibitor in bDMARDs-naive PsA showed significant improvement in ACR50 and PASI90 scores vs Placebo. No major safety signals. Skin response is excellent! @RheumNow https://t.co/yhgB8LGXh6
      RT @RichardPAConway: Redondo-Rodriguez et al. Abatacept in RA-ILD. Prospective study 38 patients. 73.6% improved/stablis

      Richard Conway RichardPAConway

      2 years 5 months ago
      Redondo-Rodriguez et al. Abatacept in RA-ILD. Prospective study 38 patients. 73.6% improved/stablised with abatacept at median 17 month follow-up @RheumNow #EULAR2022 POS0654 https://t.co/D2du0hAXIy
      RT @AurelieRheumo: JUVE-BASIS Baricitinib in JIA
      Phase 3 RCT wk12

      Cs or BioDMARDs IR

      ⚡️Time to disease flare HR 0.

      Aurelie Najm AurelieRheumo

      2 years 5 months ago
      JUVE-BASIS Baricitinib in JIA Phase 3 RCT wk12 Cs or BioDMARDs IR ⚡️Time to disease flare HR 0.24 ⚡️JIA-ACR50% 63% ⚡️% flares 17% vs. 50% in PBO Safety profile similar than adults @RheumNow #EULAR2022 LB0002 https://t.co/dX3DpB4QHT
      RT @drdavidliew: @EricFMorand up first in late-breakings
      PAISLEY: deucravacitinib (TYK2i) ph2 in SLE - add-on, steroid

      David Liew drdavidliew

      2 years 5 months ago
      @EricFMorand up first in late-breakings PAISLEY: deucravacitinib (TYK2i) ph2 in SLE - add-on, steroid wean Good outcomes: primary: SRI(4) at 32w skin/joint/LLDAS & dsDNA/C4 Safety good (like PsO/PsA) but higher dose less so Watch for: other clinical, ph3 #EULAR2022 @RheumNow https://t.co/XOQWuiHkTx
      RT @Yuz6Yusof: #POS1207 #EULAR2022 In N=98 RA patients with poor antibody response to rituximab after two doses, 19% res

      Md Yuzaiful Md Yusof Yuz6Yusof

      2 years 5 months ago
      #POS1207 #EULAR2022 In N=98 RA patients with poor antibody response to rituximab after two doses, 19% responded after 3rd dose. Associated with longer Time of vaccine from last RTX & interestingly ultra dose 200mg used in the Netherlands @RheumNow https://t.co/TTXXtOU6vp

      Podcasts

      • ACR24 - LUPUS
      • ACR24 - SPONDYLOARTHRITIS
      • ACR24 - PSORIATIC ARTHRITIS

      Catch up on Conference Podcasts

      Featured Video

      Do you get our email newsletter?

      Looking for the latest rheumatology news & trends? Sign up for the RheumNow weekday newsletter:

      This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

      Rheumnow.com is a news source dedicated to the field of Rheumatology. It is written by experts in the field, and written for rheumatologists and individuals working in related fields. Rheumnow.com provides daily updates on the site and in your inbox when you are signed up for our newsletter.

      Copyright {{ 'now'|date('Y') }} All Rights Reserved.